Dry platelet composition

Abstract

The invention features a dry platelet composition and methods of making and using the freeze-dried platelet composition.

1 - 44 . (canceled) 
     
     
         45 . A dry platelet composition, the composition comprising:
 a plurality of dry platelets; and   
       inhibitors of platelet activation comprising at least one effector of the cyclic adenosine monophosphate (cAMP) second messenger system, at least one sodium channel inhibitor, and at least one effector of the cyclic guanosine 5′ monophosphate (cGMP) second messenger system. 
     
     
         46 . The composition of  claim 45 , wherein the inhibitors of platelet activation comprise adenosine, amiloride, and sodium nitroprus side. 
     
     
         47 . The composition of  claim 46 , wherein, after hydration of the composition, the concentration in the composition: of adenosine is about 10 μM to about 1 mM; of amiloride is about 0.1 mM to about 10 mM; and of sodium nitroprusside is about 2.5 μM to about 250 μM. 
     
     
         48 . The composition of  claim 45 , wherein the at least one effector of the cAMP second messenger system is selected from the group consisting of iloprost, prostacyclin, prostaglandin E 2 , forskolin, cholera toxin, isoproterenol, 8-bromo cyclic adenosine monophosphate, dibutyl cyclic adenosine monophosphate, theophylline, isobutylmethyl xanthine, thyrotropin, and auranofin. 
     
     
         49 . The composition of  claim 45 , wherein the at least one sodium channel inhibitor is selected from the group consisting of amiloride analogues, bepridil, flecamide, saxitoxin, benzamil, and prajnalium. 
     
     
         50 . The composition of  claim 45 , wherein the at least one effector of the cGMP second messenger system is selected from the group consisting of L-arginine, nitrous oxide, SIN-1, SIN-1A, atrial natriuretic factor, vasopressin, oxytocin, and glyceril trinitrate. 
     
     
         51 . The composition of  claim 45 , further comprising one or more cryoprotective agents. 
     
     
         52 . The composition of  claim 51 , wherein the cryoprotective agent is selected from the group consisting of dimethylsulfoxide, maltodextrin, dextran, hydroxyethyl starch, glucose, polyvinyl pyrrolidone, mannitol, and combinations thereof. 
     
     
         53 . The composition of  claim 45 , further comprising dry blood plasma. 
     
     
         54 . The composition of  claim 45 , further comprising one or more extracellular matrix (ECM) components. 
     
     
         55 . The composition of  claim 54 , wherein the one or more ECM components are selected from the group consisting of collagen, elastin, fibronectin, fibrillin, laminin, decorin, fibromodulin, hyaluronic acid, and a proteoglycan. 
     
     
         56 . The composition of  claim 54 , wherein the ECM components are in particles of particulate acellular tissue matrix. 
     
     
         57 . The composition of  claim 56 , wherein the particulate acellular tissue matrix is particulate acellular dermal matrix. 
     
     
         58 . The composition of  claim 45 , wherein hydration of the dry platelet composition results in a rehydrated platelet composition with substantially the same level of at least one platelet function possessed by a sample of fresh platelets from which the dry platelet composition was derived. 
     
     
         59 . The composition of  claim 58 , wherein the at least one platelet function is the ability to aggregate. 
     
     
         60 . The composition of  claim 58 , wherein the at least one platelet function is the ability to release one or more growth factors or chemokines. 
     
     
         61 . The composition of  claim 60 , wherein the growth factor or chemokine is selected from the group consisting of transforming growth factor-β (TGF-β), members of platelet derived growth factor (PDGF) family, epidermal growth factor (EGF), members of vascular endothelial growth factor (VEGF) family, and thymosin β4. 
     
     
         62 . The composition of  claim 58 , wherein the at least one platelet function is the ability to induce cell proliferation. 
     
     
         63 . The composition of  claim 62 , wherein the cell proliferation is fibroblast proliferation. 
     
     
         64 . The composition of  claim 45 , wherein the platelets are human platelets.